Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Neoplasms 1Leukemia, Promyelocytic, Acute 1Leukemia 1Carcinoma, Non-Small-Cell Lung 1Carcinoma 1Breast Neoplasms 1

Interventions

Cyclophosphamide 3Busulfan 3Tacrolimus 2Peripheral Blood Stem Cell Transplantation 2Methotrexate 2Filgrastim 2Arsenic Trioxide 2tamibarotene 1fludarabine phosphate 1Tretinoin 1Mycophenolic Acid 1Idarubicin 1Clofarabine 1Bortezomib 1Antilymphocyte Serum 1Alemtuzumab 1AEG 35156 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Leukemia, Promyelocytic, Acute × AEG 35156 × Clear all
NCT01018069 2011-07-13

AEG35156 in Combination With High-dose Cytarabine and Idarubicin in AML Following Failure of a Single Standard Dose Cytarabine Based Frontline Induction Regimen

Aegera Therapeutics

Phase 2 Terminated
60 enrolled
Other hematologic neoplasm

Leukemia, Leukemia, Promyelocytic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡